Cgenetech (Suzhou, China) Co. Ltd. has synthesized tyrosine-protein kinase JAK2 inhibitors reported to be useful for the treatment of autoimmune diseases, myeloproliferative diseases and graft-versus-host disease.
Pharward Biotechnology Inc. Pte Ltd. has disclosed compounds acting as E3 ubiquitin-protein ligase SIAH1 modulators reported to be useful for the treatment of cocaine dependence.
Jaguar Gene Therapy LLC’s IND application for JAG-201, a gene therapy for a genetic form of autism spectrum disorder (ASD) and Phelan-McDermid syndrome (PMS; 22q13.3 deletion syndrome), has been cleared by the FDA.
Amphiphile (AMP)-modification of peptide antigens and molecular adjuvants has been previously demonstrated to enhance lymphatic delivery and retention, resulting in potent expansion of cognate endogenous T-cell responses.
Neutrophils are the immune system’s most abundant effector cells, which play a defensive role of host cells and clear pathogens by phagocytosis, degranulation and neutrophil extracellular trap (NET) release.
Radiation therapy resistance (radioresistance) is a key contributor to the failure of rectal cancer treatment, with immunosuppression playing a significant role here.
23andme Holding Co. has received FDA clearance of its IND application for 23ME-01473 (‘1473), a dual mechanism antibody and natural killer (NK) cell activator intended to treat cancer.
Vivet Therapeutics SAS has been awarded financing of €4.9 million (US$5.3 million) from the French government to advance the development of a gene therapy for the treatment of the neurodegenerative disease cerebrotendinous xanthomatosis (CTX).
Guard Therapeutics AB has presented progress within the company’s preclinical development platform, the GTX platform, aimed at developing new peptides based on the endogenous protein α-1-microglobulin.
Perioperative neurocognitive disorders (PNDs) refer to a variety of cognitive abnormalities mainly experienced by elderly patients after anesthesia procedures and include cognitive impairment and disorientation linked to oxidative stress and neuroinflammation. Insulin-like growth factor-1 (IGF-1), a neurotrophic hormone that regulates microglia-mediated neuroinflammation, may represent a therapeutic target in this context.
RSS
